太平洋医药日报：酶替代疗法Loargys获FDA批准

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 0.84% on February 25, 2025, outperforming the CSI 300 index by 0.24 percentage points, ranking 14th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included other biological products (+2.39%), hospitals (+2.04%), and medical consumables (+1.58%), while offline pharmacies (+0.32%), in vitro diagnostics (+0.33%), and medical R&D outsourcing (+0.34%) lagged behind [4]. - The approval of Loargys by the FDA for treating arginine deficiency in patients aged 2 and above is a significant development, based on positive results from the Phase 3 PEACE trial, which showed a reduction in plasma arginine levels from 354.0 μmol/L to 86.4 μmol/L [5]. Summary by Relevant Sections Market Performance - On February 25, 2025, the pharmaceutical sector's performance was +0.84%, surpassing the CSI 300 index by 0.24 percentage points, with the sector ranking 14th among 31 sub-industries [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceutical industries: Neutral [3]. Company News - Sainuo Medical reported a revenue of 525 million yuan for 2025, a year-on-year increase of 14.53%, with a net profit of 47 million yuan, up 3057.05% [6]. - United Imaging Healthcare achieved a revenue of 13.821 billion yuan in 2025, reflecting a 34.18% year-on-year growth, with a net profit of 1.888 billion yuan, up 49.60% [6]. - Huayu Pharmaceutical received FDA approval for its new drug applications for etoposide injection and fluorouracil injection, facilitating market expansion in the U.S. [6]. - Aibo Medical announced plans to acquire a 68.31% stake in Demei Medical for approximately 683 million yuan, positioning itself as a controlling subsidiary in the sports medicine sector [6].